Back to Agenda
Welcome and Session 1 Regional and Global Updates Part 1
Session Chair(s)
Renata De Lima Soares
Regulation and Health Surveillance Specialist, Anvisa, Brazil
Ana Padua, MSC, RPH
Director EU Global Regulatory and Scientific Policy , Merck Kgaa, Darmstadt, Germany (EMD Serono, US), Switzerland
This session is intended for each National Regulatory Authority (NRA) to provide a summary of the progress made on their regulatory projects as well as their priorities for 2021. Each NRA will have approximately 15-20 minutes to provide an update on progress made on several local, regional, and global projects as well as their priorities for the year that affect regulators and manufacturers/regulated sector in Latin America. A Q&A panel discussion will be held at the end of this session to provide any clarification where necessary.
Learning Objective : Upon completion of this session, the participant should be able to:
- Understand the progress made by NRAs in their projects
- Identify NRAs priorities for 2021
- Understand the impact of projects and priorities for regulators and manufacturers
Speaker(s)
Ana Pineda Zavaleta, MSC
International Regulatory Analyst, LAO, OGPS, OPLIA, OC, FDA, United States
Speakers
Carlos Junio Falconí Borja
Director Técnico de Elaboración, Evaluación y Mejora Continua de Normativa , Argencia Nacional de Regulacion, Control Y Vigilancia Sanitaria (ARCSA), Ecuador
Speakers
Heriberto Enrique García Escorza, MPA, RPH
Director, Instituto de Salud Pública de Chile, Chile
Role of the National Agency of Reference in the Combat to COVID-19 Pandemic
Olga Sofia Ponce Quiñonez
Coordinadora General Técnico de Certificaciones, Control Sanitario , Argencia Nacional de Regulacion, Control Y Vigilancia Sanitaria (ARCSA), Ecuador
Leonardo Sánchez, PHARMD
Comisionado Adjunto, Agencia de Regulación Sanitaria HONDURAS, Honduras
Speaker
Eliana Caballero
, Agencia Estatal De Medicamentos Y Tecnología En Salud (AGEMED), Bolivia
Speaker
Have an account?